JetBlue Airways Corporation (JBLU - Free Report) posted impressive traffic results for October, following which, shares of the company inched up 1.2% at the close of business on Nov 13.
Traffic measured in revenue passenger miles (RPMs), increased 9.5% year over year to 4.06 billion. Consolidated capacity (or available seat miles/ASMs) also expanded 8.9% to 4.9 billion on a year-over-year basis.
Load factor or percentage of seats filled by passengers improved 50 basis points (bps) to 82.9% in the month as traffic growth outpaced capacity expansion.
The Long Island City, NY-based low-cost carrier registered a completion factor (system wide) of 99.4% with 78.8% flights on schedule.
In the first 10 months of 2018, the carrier posted a 7.4% rise in RPMs while ASMs grew 6.4%, both on a year-over-year basis. Also, load factor rose 80 bps to 85.3%.
The company’s fourth-quarter revenue per available seat mile (RASM) is still anticipated to increase in the range of 1-4%. Additionally, the carrier expects capacity to expand between 7.5% and 9.5% in the current quarter. Consolidated operating cost per available seat mile excluding fuel is expected to decrease in the 1.5-3.5% band during the ongoing quarter. Meanwhile, fourth-quarter fuel cost, net of hedges, is projected to be $2.48 per gallon.
Zacks Rank & Key Picks
JetBlue carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader Transportation sector are Air France-KLM SA (AFLYY - Free Report) , International Consolidated Airlines Group SA and Spirit Airlines, Inc. (SAVE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Air France-KLM have rallied more than 28% in the past six months while the same of International Consolidated Airlines and Spirit Airlines has gained more than 8% and 43%, respectively, in a year.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>